Skip to main content

Table 2 Immunoglobulin G fragment crystallizable glycan distribution of IgG1 and IgG2 in patients with rheumatoid arthritis prior to and following methotrexate treatment

From: IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Type

Isotype

Glycana

Good responders

Moderate responders

Non responders

Intraindividual change

Interindividual differences

    

Prior/following

Prior

Following

   

Prior

Following

Prior

Following

Prior

Following

GR

MR

NR

(GR + MR)/NR

(GR + MR)/NR

 

IgG1

Σ[Galactosylated glycans]b

60 ± 12

63 ± 13

54 ± 13

57 ± 13

49 ± 12

47 ± 14

0.004

0.03

0.5

0.02

0.001

 

Σ[Agalactosylated glycans]c

40 ± 12

37 ± 13

46 ± 13

43 ± 13

51 ± 12

53 ± 14

0.004

0.03

0.5

0.02

0.001

 

Σ[Afucosylated glycans]d

4 ± 3

4 ± 3

3 ± 2

4 ± 2

3 ± 1

4 ± 2

0.8

0.4

0.2

0.2

1

 

Σ[Bisected glycans]e

12 ± 4

13 ± 4

12 ± 2

14 ± 3

13 ± 3

14 ± 5

0.2

0.0003

0.3

0.7

1

 

Σ[Sialylated glycans]f

4 ± 4

4 ± 3

3 ± 2

4 ± 3

2 ± 2

3 ± 2

0.5

0.3

0.5

0.1

0.04

IgG2

Σ[Galactosylated glycans]g

52 ± 14

54 ± 15

45 ± 13

47 ± 13

40 ± 11

39 ± 11

0.2

0.1

0.7

0.01

0.003

 

Σ[Agalactosylated glycans]h

48 ± 14

46 ± 15

55 ± 13

53 ± 13

60 ± 11

61 ± 11

0.2

0.1

0.7

0.01

0.003

 

Σ[Bisected glycans]i

7 ± 3

8 ± 3

6 ± 2

7 ± 3

7 ± 3

7 ± 3

0.01

0.004

1

0.7

0.5

 

Σ[Sialylated glycans]j

6 ± 5

6 ± 5

5 ± 3

5 ± 4

4 ± 2

4 ± 2

0.5

0.9

0.9

0.02

0.1

aGal/Gal ratio

All IgG1

Log [Σ(Agalactosylated glycans)/Σ(galactosylated glycans)]

−0.18 ± 0.24

−0.25 ± 0.26

−0.08 ± 0.25

−0.14 ± 0.25

0.02 ± 0.21

0.05 ± 0.26

0.003

0.03

0.42

0.03

0.006

All IgG2

Log [Σ(agalactosylated glycans)/Σ(galactosylated glycans)]

−0.05 ± 0.26

−0.07 ± 0.27

0.09 ± 0.24

0.05 ± 0.24

0.19 ± 0.21

0.20 ± 0.22

0.2

0.05

0.62

0.007

0.006

Main IgG1

Log[FA2/(FA2G1 + FA2G2)]

−0.17 ± 0.21

−0.24 ± 0.23

−0.07 ± 0.23

−0.13 ± 0.22

0.02 ± 0.20

0.05 ± 0.24

0.001

0.02

0.4

0.02

0.001

Main IgG2

Log[FA2/(FA2G1 + FA2G2)]

0.02 ± 0.23

−0.05 ± 0.24

0.11 ± 0.23

0.06 ± 0.21

0.20 ± 0.21

0.22 ± 0.20

0.1

0.02

0.6

0.02

0.001

Bisected IgG1

Log[FA2B/(FA2BG1 + FA2BG2)]

−0.15 ± 0.29

−0.21 ± 0.29

−0.08 ± 0.26

−0.12 ± 0.25

0.06 ± 0.24

0.07 ± 0.26

0.03

0.1

0.7

0.02

0.002

Bisected IgG2

Log[FA2B/FA2BG1]

0.40 ± 0.35

0.35 ± 0.42

0.68 ± 0.48

0.52 ± 0.46

0.76 ± 0.38

0.70 ± 0.29

0.4

0.03

0.3

0.1

0.02

Afucosylated IgG1

Log[A2/(A2G1 + A2G2)]

−0.51 ± 0.62

−0.72 ± 0.71

−0.36 ± 0.59

−0.53 ± 0.58

−0.17 ± 0.56

−0.19 ± 0.56

0.02

0.04

0.8

0.1

0.01

  1. Abbreviations: aGal/Gal Ratio between agalactosylated and galactosylated glycans, GR Good response, MR Moderate response, NR No response
  2. Patients are grouped according to response to MTX. Figures are given for average values (%) ± SD. p Values <0.02 remained significant following false discovery rate correction
  3. aGlycan abbreviations are provided in Fig. 2a legend
  4. bΣ[IgG1: A2G1, A2G2, FA2G1, FA2BG1, FA2G1S1, FA2G2, FA2BG2, FA2G2S1]
  5. cΣ[IgG1: FA2, FA2B, A2 and A2B]
  6. dΣ[IgG1: A2, A2B, A2G1, A2G2]
  7. eΣ[IgG1: A2B, FA2B, FA2BG1, FA2BG2]
  8. fΣ[IgG1: FA2G1S1, FA2G2S1]
  9. gΣ[IgG2: FA2G1, FA2BG1, FA2G2, FA2G1S1, FA2G2, FA2G2S1]
  10. hΣ[IgG2: FA2, FA2B]
  11. iΣ[IgG2: FA2B, FA2BG1]
  12. jΣ[IgG2: FA2G1S1, FA2G2S1]
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us